A Two-Cohort, Single- and Repeat Dose Study to Examine the Pharmacokinetics, Tolerability, and Safety of Ready to Use Exenatide Once Weekly in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 31 Aug 2015
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Amylin Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 02 May 2014 Planned End Date changed from 1 Sep 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 02 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.